Cargando…

Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity

The identification of molecular biomarkers in CSF from individuals affected by Huntington disease may help improve predictions of disease onset, better define disease progression and could facilitate the evaluation of potential therapies. The primary objective of our study was to investigate novel C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caron, Nicholas S, Haqqani, Arsalan S, Sandhu, Akshdeep, Aly, Amirah E, Findlay Black, Hailey, Bone, Jeffrey N, McBride, Jodi L, Abulrob, Abedelnasser, Stanimirovic, Danica, Leavitt, Blair R, Hayden, Michael R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746690/ https://www.ncbi.nlm.nih.gov/pubmed/36523269 http://dx.doi.org/10.1093/braincomms/fcac309

Ejemplares similares

Intercellular Interactomics of Human Brain Endothelial Cells and Th17 Lymphocytes: A Novel Strategy for Identifying Therapeutic Targets of CNS Inflammation
por: Haqqani, Arsalan S., et al.
Publicado: (2011)

Proteome of the Luminal Surface of the Blood–Brain Barrier
por: Hill, Jennifer J., et al.
Publicado: (2021)

Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer's Disease
por: Leclerc, Benoît, et al.
Publicado: (2013)

Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells
por: Haqqani, Arsalan S, et al.
Publicado: (2013)

Transport characteristics of a novel peptide platform for CNS therapeutics
por: Bertrand, Yanick, et al.
Publicado: (2010)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression
por: Southwell, Amber L., et al.
Publicado: (2015)

Brain Delivery of IGF1R5, a Single-Domain Antibody Targeting Insulin-like Growth Factor-1 Receptor
por: Yogi, Alvaro, et al.
Publicado: (2022)

Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range
por: Findlay Black, Hailey, et al.
Publicado: (2020)

Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease
por: Fang, Qiaojun, et al.
Publicado: (2009)

Zika virus crosses an in vitro human blood brain barrier model
por: Alimonti, Judie B., et al.
Publicado: (2018)

Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity
por: Haqqani, Arsalan S., et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer’s Disease in Rat and Dog
por: Lessard, Etienne, et al.
Publicado: (2022)

Preface to the Special Issue on “Sleep and Circadian Disorder in Huntington’s Disease”
por: Leavitt, Blair R., et al.
Publicado: (2023)

Differential Expression of ABC Transporter Genes in Brain Vessels vs. Peripheral Tissues and Vessels from Human, Mouse and Rat
por: Zhang, Wandong, et al.
Publicado: (2023)

Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
por: Mazarei, Gelareh, et al.
Publicado: (2015)

Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human
por: Zhang, Wandong, et al.
Publicado: (2020)

Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier
por: Stanimirovic, Danica B., et al.
Publicado: (2018)

Mouse embryonic stem cell-derived blood–brain barrier model: applicability to studying antibody triggered receptor mediated transcytosis
por: Jezierski, Anna, et al.
Publicado: (2023)

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease
por: Van Raamsdonk, Jeremy M, et al.
Publicado: (2006)

Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease
por: Caron, Nicholas S, et al.
Publicado: (2020)

DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease
por: Schmidt, Mandi E., et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin
por: Tan, Z, et al.
Publicado: (2015)

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
por: Niemela, Valter, et al.
Publicado: (2020)

Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies
por: Iqbal, U, et al.
Publicado: (2010)

Alterations of fractional anisotropy throughout cortico-basal ganglia gray matter in a macaque model of Huntington’s Disease
por: Weiss, Alison R., et al.
Publicado: (2023)

A novel human induced pluripotent stem cell blood-brain barrier model: Applicability to study antibody-triggered receptor-mediated transcytosis
por: Ribecco-Lutkiewicz, Maria, et al.
Publicado: (2018)

Potential biomarkers to follow the progression and treatment response of Huntington’s disease
por: Disatnik, Marie-Hélène, et al.
Publicado: (2016)

Longitudinal expression changes are weak correlates of disease progression in Huntington’s disease
por: Mitchell, Christopher T, et al.
Publicado: (2020)

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease
por: Lowe, Alexander J., et al.
Publicado: (2020)

Large Animal Models of Huntington’s Disease: What We Have Learned and Where We Need to Go Next
por: Howland, David, et al.
Publicado: (2020)

Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses
por: Bone, Jeffrey N., et al.
Publicado: (2022)

Altered Intracortical T(1)-Weighted/T(2)-Weighted Ratio Signal in Huntington’s Disease
por: Rowley, Christopher D., et al.
Publicado: (2018)

A Computational Cognitive Biomarker for Early-Stage Huntington’s Disease
por: Wiecki, Thomas V., et al.
Publicado: (2016)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI
por: Rodrigues, Filipe B., et al.
Publicado: (2019)

Disease-related Huntingtin seeding activities in cerebrospinal fluids of Huntington’s disease patients
por: Lee, C. Y. Daniel, et al.
Publicado: (2020)

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease
por: Rodrigues, Filipe B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pbmfqnu3o2i55bo2ank5qpq7pk